Ryno Nasal Spray 1md contains Fluticasone Furoate. Ryno Nasal Spray 1md uses:
Ryno Nasal Spray 1md nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.
|Brand Name:||Ryno Nasal Spray 1md|
|Therapeutic Class:||Nasal Steroid Preparations|
|Manufacturer:||LINCOLN PHARMACEUTICALS LTD|
|Last Updated:||2020-11-22 18:15:00|
Ryno Nasal Spray 1md contains Fluticasone Furoate 27.5 Mcg. Ryno Nasal Spray 1md doses
Adults & Children over 12 years: 2 sprays in each nostril once a day. In some cases 2 sprays into each nostril twice daily, not exceeding 4 sprays.
Children under 12 years (2-11 Years): 1 spray in each nostril once a day. Patients should use Ryno Nasal Spray 1md nasal spray at regular intervals as directed since its effectiveness depends on its regular use.
Children (under 2 years of age): There are no data to recommend use of Ryno Nasal Spray 1md Nasal Spray for the treatment of seasonal or perennial allergic rhinitis in children under 2 years of age.
How to use the Nasal Spray
Eosinophilic conditions, adrenal insufficiency, growth retardation, Cushing's syndrome, decreased bone density, cataract, glaucoma. Rarely, psychological effects.
Ryno Nasal Spray 1md is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Like other corticosteroids Ryno Nasal Spray 1md is found to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g.- histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation.
Patients taking Ryno Nasal Spray 1md nasal spray should be periodically monitored for signs of adverse effects on the nasal mucosa such as epistaxis, nasal ulceration and impaired wound healing. Avoid using the drug in patients with recent nasal ulcers, nasal surgery, or nasal trauma. Closely monitor patients with a history of increased intraocular pressure, glaucoma and hypersensitivity reactions (including anaphylaxis, angioedema, rash, and urticaria). Besides, potential worsening of existing fungal, bacterial, viral, or parasitic infections or ocular herpes simplex, hypercorticism and growth retardation may occur after the administration of Ryno Nasal Spray 1md nasal spray.
Potent inhibitors of cytochrome P450 3A4 (CYP3A4) may increase exposure to Ryno Nasal Spray 1md. Coadministration of ritonavir is not recommended. Use caution with coadministration of other potent CYP3A4 inhibitors, such as ketoconazole.
Special instruction: Patients should be instructed that the device must be primed: before first use, and if the cap is left off or if the device does not seem to be working or if the nasal spray has not been used for 30 days or more. In order to prime the device, the nasal spray needs to be shaken vigorously for about 10 seconds with the cap on. The patient must then press the button firmly all the way in, approximately 6 times until a fine mist is seen. Once primed, the patient must shake the nasal spray vigorously each time before use.
Pregnancy: Plasma Ryno Nasal Spray 1md concentrations were typically non-quantifiable and therefore potential for reproductive toxicity is expected to be very low.
Lactation: The excretion of Ryno Nasal Spray 1md into human breast milk has not been investigated.
Ryno Nasal Spray 1md nasal spray is contraindicated in patients with a hypersensitivity to any of its ingredients.
Pediatric use: The safety and effectiveness of Ryno Nasal Spray 1md in children younger than 2 years have not been established.
Geriatric use: In general, dose selection for the elderly patient should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Use in hepatic impairment: Use Ryno Nasal Spray 1md with caution in patients with severe hepatic impairment.
Use in renal impairment: No dosage adjustment is required in patients with renal impairment.
Ryno Nasal Spray 1md Nasal Spray price in India 313.65